Intentar ORO - Gratis
Scheme to build bulk drugs' R&D, capacity in works
Business Standard
|June 08, 2026
The government is working on a new support scheme for the bulk drugs industry even as it rules out any blanket increase in medicine prices despite cost pressures arising from the West Asia crisis, Pharmaceuticals Secretary Manoj Joshi has said.
In an interview with Business Standard, Joshi said the proposed scheme would go beyond the production-linked incentive (PLI) approach to focus on long-term capacity creation, research and development (R&D), and stronger academia-industry partnerships.
Esta historia es de la edición June 08, 2026 de Business Standard.
Suscríbete a Magzter GOLD para acceder a miles de historias premium seleccionadas y a más de 9000 revistas y periódicos.
¿Ya eres suscriptor? Iniciar sesión
MÁS HISTORIAS DE Business Standard
Business Standard
Fertiliser subsidy Bill likely to double in FY27
However, the official said there is no change in the Centre’s ‐12.2 trillion capital expenditure plan for FY27.
1 mins
June 10, 2026
Business Standard
India Inc's payout to shareholders grows slower than profit for third straight yr
The modest increase in shareholder payouts during FY26 was driven entirely by a surge in share buybacks, while equity dividends declined marginally.
1 mins
June 10, 2026
Business Standard
Govt eases sourcing norms to promote domestic solar PV
Speeds up approvals for higher wattage modules
2 mins
June 10, 2026
Business Standard
Constitution doesn't permit govt to direct judiciary: Meghwal
Union Law and Justice Minister Arjun Ram Meghwal on Tuesday asserted that the Constitution does not permit the government to direct or interfere in the judiciary’s functioning.
1 min
June 10, 2026
Business Standard
SpaceX IPO marks the peak of AI euphoria, says Chris Wood
The SpaceX initial public offering (IPO) could well be the peak of the euphoria surrounding artificial intelligence (AI), wrote Christopher Wood, global head of equity strategy, Jefferies, in his weekly note to investors, GREED & fear.
2 mins
June 10, 2026
Business Standard
Lilly claims its oral GLP-1 outperformed oral semaglutide in diabetes trial
US drugmaker Eli Lilly on Tuesday claimed positive safety and efficacy results for its oral glucagon-like peptide (GLP-1) drug orforglipron in Type-II diabetes patients, including greater reductions in A1C and body weight than oral semaglutide.
2 mins
June 10, 2026
Business Standard
TCS share in group mcap falls to lowest since listing
A continued decline in the share price and market capitalisation (mcap) of IT services major Tata Consultancy Services (TCS) has led to a sharp fall in its contribution to the Tata Group’s overall mcap.
1 min
June 10, 2026
Business Standard
₹95,692 crore interim allocation under VB-G RAMG
With El Nino looming on the horizon, the Centre released an interim sum of ₹95,692 crore under the newly introduced Viksit Bharat Guarantee for Rozgar and Ajeevika Mission (Grameen) scheme on Tuesday for a seamless transition from MGNREGA.
1 mins
June 10, 2026
Business Standard
Apple bets on overdue Siri fix to close AI gap
Apple opened WWDC 2026 with platform updates, but its headline move was a reset of its artificial intelligence push centred on Siri.
1 mins
June 10, 2026
Business Standard
Tea Board pins hope on new mkts as Iran war weighs on trade
The Tea Board is banking on market diversification to cushion the impact of the ongoing West Asia conflict and keep tea exports at last year’s level.
1 mins
June 10, 2026
Listen
Translate
Change font size